Live symbol workspace

PFE market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $28.32

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$26.90

Resistance

$29.74

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$28.32

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Over the last 30 days, AI sentiment for PFE skewed neutral (3 of 4 scored calls).

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

31%

▲ 0.9 pts vs previous week

Avg confidence across 32 calls in the last 7 days

What sources say

Neutral 3 articles

Ebola Crisis Exposes Congo's Fragile Health System

Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?

Pfizer (PFE) Reaffirms FY 2026 Outlook Amid Leadership Change

Bearish 1 article

Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

PFE News Intelligence (14 articles)

AI-curated news influencing PFE price, sentiment, and trend

Explore All PFE News with AI Analysis

Stocks

3 months, 2 weeks ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease …

Impact on PFE: The announcement is likely to have a positive impact on Pfizer's (PFE) …

Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine after a … High (80%)

View full analysis →

MarketWatch 80% confidence

Economy

3 months, 3 weeks ago

Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

Impact on PFE: The increased demand for weight-loss drugs could lead to a surge in …

The recent surge in demand for new weight-loss drugs is expected to benefit top S&P … High (70%)

View full analysis →

Yahoo Finance 70% confidence